Nereus Capsule
NDC Package 43068-585-01
Package Information
Nereus (tradipitant) capsules is nEREUS is indicated for the prevention of vomiting induced by motion in adults. This formulation utilizes a capsule delivery system. Marketed by Vanda Pharmaceuticals Inc., this product is identified by NDC 43068-585 and is authorized under FDA application NDA220152.
Identification & Billing
- RxCUI: 2739511 - tradipitant 85 MG Oral Capsule
- RxCUI: 2739517 - NEREUS 85 MG Oral Capsule
- RxCUI: 2739517 - tradipitant 85 MG Oral Capsule [Nereus]
- RxCUI: 2739517 - Nereus 85 MG Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43068 - Vanda Pharmaceuticals Inc.
- 43068-585 - Nereus
- 43068-585-01 - 60 CARTON in 1 BOTTLE / 1 CAPSULE in 1 CARTON
- 43068-585 - Nereus
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (43068-585). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43068-585-01 identifies a specific commercial package of 60 carton in 1 bottle / 1 capsule in 1 carton of Nereus, a human prescription drug labeled by Vanda Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This capsule is formulated for oral use and contains tradipitant as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Vanda Pharmaceuticals Inc. on March 31, 2026. The current certification is valid through December 31, 2027.
How is this Vanda Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43068058501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.